logo

Ardelyx, Inc (ARDX)



Trade ARDX now with
  Date
  Headline
11/12/2021 8:21:59 AM Ardelyx, Inc. Q3 Net Loss $43.6 Mln Vs. Net Loss $18.1 Mln Last Year
10/13/2021 8:13:21 AM Ardelyx Continues To Await Clarity From FDA On Path Forward For Approval Of Tenapanor For Hyperphosphatemia
9/3/2021 8:04:36 AM Ardelyx Announces Publication Of 52-week Phase 3 PHREEDOM Trial In American Society Of Nephrology Journal, Kidney360
8/13/2021 8:04:21 AM Ardelyx Q2 Net Loss $45.2 Mln Vs. Loss $25.0 Mln Prior Year
4/14/2021 8:09:37 AM Ardelyx Partner, Kyowa Kirin, Announces Initiation Of Phase 3 Studies Of Tenapanor For Hyperphosphatemia In Japan
4/12/2021 8:21:35 AM Ardelyx To Present Data From NORMALIZE At The ISN World Congress Of Nephrology 2021
3/8/2021 8:08:59 AM Ardelyx FY Loss Narrows To $94.3 Mln From $94.9 Mln Prior Year
10/12/2020 8:11:23 AM Ardelyx Presents Data Supporting Efficacy And Safety Of Tenapanor At ASN's Kidney Week 2020
9/15/2020 9:59:56 AM Stock Alert: Ardelyx Down 6%
9/15/2020 8:28:19 AM Ardelyx: FDA Accepts NDA Of Tenapanor For Control Of Serum Phosphorus In Adult Patients With CKD On Dialysis
8/6/2020 8:06:49 AM Ardelyx, Inc. Q2 Net Loss $25 Mln Vs. Net Loss $25.5 Mln Last Year
6/30/2020 8:17:11 AM Ardelyx Submits NDA To FDA For Tenapanor For The Control Of Serum Phosphorus In Adult Patients With CKD On Dialysis
6/15/2020 8:06:53 AM Ardelyx Announces Positive Second Data Analysis From NORMALIZE Phase 4 Study Of Tenapanor In CKD Patients On Dialysis
6/8/2020 4:02:58 PM Ardelyx Appoints Justin Renz As CFO
5/18/2020 4:04:43 PM Ardelyx Appoints Susan Rodriguez As Chief Commercial Officer